Morning Overview on MSN
A targeted drug won approval for a hard-to-treat form of advanced prostate cancer
Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...
Morning Overview on MSN
Capivasertib won FDA approval for a hard-to-treat form of prostate cancer
Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.
The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...
- Fundingwill support Phase 1b/2a clinical trial of MVB-101, a prostate-specific membrane antigen x folate receptor alpha (PSMA x FRα) targeted drug conjugate - - Exclusive license to MVB-101, ...
Daniel George, MD, Director of Genitourinary Oncology at Duke Cancer Institute and investigator for the CAPItello-281 trial, said: “Patients with PTEN-deficient metastatic hormone-sensitive prostate ...
Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of ...
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer Based on results of CAPItello-281 which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results